文献速递膀胱癌与上尿路尿路上皮癌

淋巴结阳性膀胱癌治疗趋势与结局比较:国家癌症数据库分析

Trends in Treatment Strategies and Comparison of Outcomes in Lymph Node Positive Bladder Cancer: An Analysis of the National Cancer Database.
PubMed 文献 · Urology · 2020-08-29

基于国家癌症数据库2006–2014年3241例cT2-4N1-3M0淋巴结阳性膀胱癌患者,比较根治性膀胱切除联合化疗与单纯放化疗等策略的生存。新辅助与辅助化疗生存无差异但均优于单纯膀胱切除;新辅助化疗后达pT0N0者5年总生存约85%。新辅助化疗使用增加,辅助化疗与单纯膀胱切除减少。

要点

  • 淋巴结阳性膀胱癌中,化疗联合根治性膀胱切除生存最佳。
  • 新辅助与辅助化疗生存无显著差异,均优于单纯膀胱切除。
  • 新辅助化疗后达pT0N0者5年总生存约85%。

核心结论

  • 化疗联合根治性膀胱切除对淋巴结阳性膀胱癌显示最佳生存结局。
  • 新辅助化疗与辅助化疗之间无显著生存差异。
  • 新辅助化疗后达pT0N0与约85%的5年总生存率相关。

研究设计与样本

  • 回顾性队列研究,查询国家癌症数据库2006–2014年cT2-4N1-3M0淋巴结阳性膀胱癌患者共3241例。
  • 按治疗分为单纯根治性膀胱切除、新辅助化疗、辅助化疗、放化疗、单纯化疗或无确定性治疗。
  • 采用Kaplan-Meier和多变量Cox比例风险回归分析生存,逻辑回归分析病理降期与治疗趋势。

主要发现

  • 3241例中cN1占46%、cN2占44%、cN3占10%;新辅助化疗418例、辅助化疗591例、单纯膀胱切除567例、放化疗392例、单纯化疗1068例、无确定性治疗205例。
  • 新辅助化疗与辅助化疗总生存无差异,但两者均优于单纯根治性膀胱切除。
  • 其余治疗组生存结局均劣于新辅助化疗。
  • 新辅助化疗后病理降期至pT0的校正比值比为26.39、至pN0的校正比值比为6.88,均高于单纯膀胱切除。
  • 新辅助化疗使用增加,辅助化疗和根治性膀胱切除下降,放化疗与无确定性治疗不变。

关键数值与推荐

  • 新辅助化疗后达pT0N0者5年总生存率约85%。
  • 放化疗肿瘤学结局劣于围手术期化疗联合根治性膀胱切除,但生存优于单纯膀胱切除或单纯化疗。

临床怎么用

  • 对淋巴结阳性膀胱癌优先考虑化疗联合根治性膀胱切除。
  • 新辅助化疗与辅助化疗均可接受,选择可结合病理降期信息与患者情况。
  • 新辅助化疗后达pT0N0提示较好长期生存,可用于预后咨询。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To utilize a national dataset to compare outcomes and demonstrate trends in treatment for lymph node positive bladder cancer (N+ BC). METHODS: The National Cancer Database (2006-2014) was queried for cT2-4N1-3M0 N+ BC patients treated with radical cystectomy alone (RC), neoadjuvant chemotherapy (NAC), adjuvant chemotherapy (AC), chemoradiation (CRT), chemotherapy alone (CT), or no definitive treatment (NT). Survival by treatment was analyzed using Kaplan-Meier and multivariable Cox-proportional hazards regression. Pathologic down-staging was analyzed using univariable and multivariable logistic regression models. A univariable logistic regression model of treatment by year identified treatment trends. RESULTS: Among 3241 patients (cN1, 46%; cN2, 44%; cN3 10%), the majority underwent combined chemotherapy and RC (NAC, 418; AC, 591; RC, 567; CRT, 392; CT, 1068; NT, 205). Overall survival did not differ between NAC and AC, but both had improved survival compared to RC. All other treatment groups had worse survival outcomes compared to NAC. Down-staging to pT0 (adjusted odds ratio = 26.39) and pN0 (adjusted odds ratio = 6.88) was higher for NAC than RC. Utilization of NAC has increased, AC and RC has declined, and CRT and NT is unchanged. CONCLUSION: Combined chemotherapy and RC demonstrates best survival outcomes for N+ BC, with complete pathologic response to pT0N0 after NAC associated with a 5-year overall survival rate of ∼85%. However, there is no significant difference between NAC and AC. CRT is associated with worse oncologic outcomes compared to RC with perioperative chemotherapy, but improved survival compared to RC or CT.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Darwish C, Sparks A, Amdur R, et al. Trends in Treatment Strategies and Comparison of Outcomes in Lymph Node Positive Bladder Cancer: An Analysis of the National Cancer Database. Urology. 2020. PMID: 32866509. doi:10.1016/j.urology.2020.06.091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。